Patient-reported outcome during radiotherapy for head and neck cancer: the use of different PRO questionnaires

Steen-Olsen, Emma Balch; Stormoen, Dag Rune; Kristensen, Claus Andrup; Vogelius, I.R.; Holländer-Mieritz, Cecilie; Pappot, Helle

doi:10.1007/s00405-022-07364-0

Cited by 5 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One-third of patients declined inclusion primarily because they could not oversee participation because they would find it too demanding. Our experience from other studies in this patient group is that around half of the patients will decline participation primarily because they are exhausted, overwhelmed by the treatment regimen, or a lack of personal resources [2,26]. A healthcare professional's incentive to ask a patient to participate can be affected by several causes, e.g., the individual healthcare professional's opinion on whether they find the patient suited for the project, their knowledge of new technologies, a busy work program, or competing protocols [27].…”

Section: Discussionmentioning

confidence: 99%

Feasibility of Using Wearables for Home Monitoring during Radiotherapy for Head and Neck Cancer—Results from the OncoWatch 1.0 Study

Holländer-Mieritz

Steen-Olsen²,

Kristensen³

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

Background: Consumer wearables allow objective health data monitoring, e.g., of physical activity and heart rate, which might change over a cancer treatment course. Patients with head and neck cancer (HNC) receiving radiotherapy (RT) with curative intent typically experience side effects such as pain, decreased appetite, and dehydration, which may lead to hospitalizations. Therefore, health data monitoring could be important to understand a patient’s condition outside the hospital. The OncoWatch 1.0 study investigated the feasibility of using smartwatches for patients with HNC receiving RT. Methods: This study was a prospective, single-cohort feasibility study. The inclusion criteria were patients ≥ 18 years of age who planned to receive curatively intended radiotherapy for HNC. Consenting patients were asked to wear a smartwatch during RT and until two weeks after the end of RT. The primary endpoint was adherence. The secondary endpoints were data acquisition and variations in heart rate and physical activity. Results: Ten patients were included, with a median age of 62 years and eight males. The adherence rate for wearing the watch >12 h/d over the study period was 31%. The data acquisition rate was 61%. Conclusions: Although the primary endpoint was not reached, new knowledge has been established, including the secure data setup and key points that need to be addressed in future studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Feasibility of Using Wearables for Home Monitoring during Radiotherapy for Head and Neck Cancer—Results from the OncoWatch 1.0 Study

Holländer-Mieritz

Steen-Olsen²,

Kristensen³

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…The FACT-H&N investigates the situation of patients seven days before the day of investigation, and the specific subscale include Physical Well-being (PWB), Social/Family Well-being (SWB), Emotional Well-being (EWB), Functional Well-being (FWB) and Head & Neck Cancer Subscale (HNCS), with a total of 39 items. The scores of the items contained in each domain were summed to obtain the crude score of this domain, and the scores of these five domains were summed to obtain the total score, which ranged from 0 to 148, where a higher overall score indicates a better corresponding quality of life (25,26).…”

Section: Instruments Fact-handnmentioning

confidence: 99%

Mapping study of papillary thyroid carcinoma in China: Predicting EQ-5D-5L utility values from FACT-H&N

Huang

Peng²,

Chen³

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

ObjectiveTo develop a mapping algorithm that can be used to predict EQ-5D-5L health utility scores from FACT-H&N and obtain health utility parameters for Chinese patients with papillary thyroid carcinoma (PTC), which can be used for cost-utility analysis in health economic.MethodsA total of 1,050 patients with PTC from a tertiary hospital in China were included, and they completed FACT-H&N and EQ-5D-5L. Four mapping algorithms of direct mapping functions were used to derive the models: Ordinary least squares (OLS), Tobit model (Tobit), Two-part model (TPM), and Beta mixture regression model (Beta). The goodness-of-fit of models was assessed by the mean absolute error (MAE), root mean square error (RMSE), Akaike information criteria (AIC), Bayesian information criteria (BIC), and absolute error (AE). A fivefold cross-validation method was used to test the stability of the models.ResultsThe mean utility value of the EQ-5D-5L was 0.870 ± 0.094. The mean EQ-VAS score was 76.5 ± 13.0. The Beta mixture regression model mapping FACT-H&N to EQ-5D-5L achieved the best performance [fivefold cross-validation MAE = 0.04612, RMSE = 0.06829, AIC = −2480.538, BIC = −2381.137, AE > 0.05 (%) = 32.48, AE > 0.1 (%) = 8.95]. The independent variables in this model were Physical Well-Being (PWB), Emotional Well-Being (EWB), Head & Neck Cancer Subscale (HNCS) scores and its square term and interaction term scores.ConclusionsThis study calculated the health utility score of Chinese patients with PTC. The reported algorithms can be used to map the FACT-H&N into the EQ-5D-5L, which can be applied in the cost-utility related study of patients with PTC.

show abstract

“…The patient-reported content validity index scores were excellent, and weak bidirectional correlations were found with resilience, depression, and anxiety. Another study found that lower QoL scores at diagnosis and during the first year after diagnosis have a predictive value for patients with head and neck squamous cell carcinoma, independent of other factors, predicting lower overall survival [2,3], and another study examined the correlation between three commonly used instruments for assessing the quality of life of 33 head and neck cancer patients at Mato Grosso Cancer Hospital in Brazil, revealing a positive correlation [31,38,39]. None of the studies did predictive analysis.…”

Section: Discussionmentioning

confidence: 99%

“…Due to the difficulty in mouth opening and swallowing, the majority of oral cancer patients only report when the condition is in advanced stages. They also exhibit anxiety about surviving a cancer diagnosis and receiving future treatment [2,3]. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module (EORTC QLQ-HN43) is a revised and updated version of the Head and Neck Cancer Module (QLQ-HN35) [4,5].…”

Section: Background and Introductionmentioning

confidence: 99%

Light gradient boosting-based prediction of quality of life among oral cancer-treated patients

Ramalingam,

Yadalam,

Ramani

et al. 2024

BMC Oral Health

View full text Add to dashboard Cite

Background and introduction Statisticians rank oral and lip cancer sixth in global mortality at 10.2%. Mouth opening and swallowing are challenging. Hence, most oral cancer patients only report later stages. They worry about surviving cancer and receiving therapy. Oral cancer severely affects QOL. QOL is affected by risk factors, disease site, and treatment. Using oral cancer patient questionnaires, we use light gradient Boost Tree classifiers to predict life quality. Methods DIAS records were used for 111 oral cancer patients. The European Organisation for Research and Treatment of Cancer’s QLQ-C30 and QLQ-HN43 were used to document the findings. Anyone could enroll, regardless of gender or age. The IHEC/SDC/PhD/OPATH-1954/19/TH-001 Institutional Ethical Clearance Committee approved this work. After informed consent, patients received the EORTC QLQ-C30 and QLQ-HN43 questionnaires. Surveys were in Tamil and English. Overall, QOL ratings covered several domains. We obtained patient demographics, case history, and therapy information from our DIAS (Dental Information Archival Software). Enrolled patients were monitored for at least a year. After one year, the EORTC questionnaire was retaken, and scores were recorded. This prospective analytical exploratory study at Saveetha Dental College, Chennai, India, examined QOL at diagnosis and at least 12 months after primary therapy in patients with histopathologically diagnosed oral malignancies. We measured oral cancer patients’ quality of life using data preprocessing, feature selection, and model construction. A confusion matrix was created using light gradient boosting to measure accuracy. Results Light gradient boosting predicted cancer patients’ quality of life with 96% accuracy and 0.20 log loss. Conclusion Oral surgeons and oncologists can improve planning and therapy with this prediction model.

show abstract

Patient-reported outcome during radiotherapy for head and neck cancer: the use of different PRO questionnaires

Cited by 5 publications

References 41 publications

Feasibility of Using Wearables for Home Monitoring during Radiotherapy for Head and Neck Cancer—Results from the OncoWatch 1.0 Study

Feasibility of Using Wearables for Home Monitoring during Radiotherapy for Head and Neck Cancer—Results from the OncoWatch 1.0 Study

Mapping study of papillary thyroid carcinoma in China: Predicting EQ-5D-5L utility values from FACT-H&N

Light gradient boosting-based prediction of quality of life among oral cancer-treated patients

Contact Info

Product

Resources

About